Sentinel Group announces the launch of its specialized Health Reimbursement Arrangement (HRA), offering targeted coverage for GLP-1 medications such as Ozempic® and Wegovy®. As employee interest in GLP-1 therapy rises, the Sentinel HRA gives employers a practical and cost-conscious way to address workforce needs while maintaining budget oversight.
GLP-1 medications have seen substantial growth in recent years, with usage among non-diabetic patients increasing by 700% from 2019 to 2023. Despite their popularity, many traditional health plans, including Medicare, do not cover these medications for weight loss, which presents challenges for employers wanting to support employees’ health goals. The Sentinel HRA helps fill this gap by allowing employers to provide access to GLP-1 medications with defined cost controls, including annual reimbursement limits and specific eligibility criteria.
"Our HRA solution allows employers to address growing demand for GLP-1 medications in a manageable and compliant way," said Scott Riordan, Head of Health & Welfare at Sentinel Group. "With flexibility in benefit design, we aim to create value for both employers and employees while maintaining regulatory compliance."
In addition to financial support, the HRA provides a user-friendly claims process available through Sentinel’s website and mobile app. The program also includes employee education and compliance resources, while also helping integrate GLP-1 coverage alongside other health benefits. Ongoing customer service and guidance are key parts of the offering.
Employers who add this benefit may see improved employee satisfaction and engagement. Sentinel’s reporting tools offer insights into program use, assisting businesses in assessing and adjusting their benefits as needed.
Sentinel balances compliance with ease of use, aiming to make plan implementation straightforward for employers.
With more than 6,000 clients and experience administering more than 267,000 participant plans, Sentinel focuses on providing adaptable solutions for today’s workplace. Employers interested in learning more or requesting a proposal for GLP-1 coverage through Sentinel’s HRA can contact us.
Sources:
- GLP-1 agonists: US sees 700% increase over four years in number of patients without diabetes starting treatment, BMJ 2024;386:q1645
- The increase in appetite for obesity drugs: https://www.jpmorgan.com/insights/global-research/current-events/obesity-drugs
This website uses cookies. By accepting the use of cookies, this message will close and you will receive the optimal website experience. For more information on our cookie policy, please visit our Privacy Policy.
